HPV Vaccine Guidelines Get Thumbs Up
The American Cancer Society (ACS) has given its endorsement to updated human papillomavirus (HPV) vaccination guidelines.
The “Change” Doesn’t Have to Be the End
Women often dread menopause, recounting the hot flashes and mood swings of their mothers. A new review offers some insight into what it really means to go through the "change of life."
What You Need to Know About the HPV Vaccine
January is Cervical Health Awareness Month, a time to raise awareness about how women can protect themselves from HPV and cervical cancer.
First Women's Libido Rx Gets Green Light
The first-ever treatment for a sexual desire disorder just got a nod of approval from the US Food and Drug Administration (FDA) — but it came with a warning.
Hypoactive Sexual Desire Disorder Rx Approved
The U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Preventing Cancer with a Pill
They're proven to help prevent pregnancy, and new evidence suggests birth control pills may also prevent one type of cancer.
Breathe Easy, Parents: Vaccine Not Tied to More STDs
Some parents have raised concerns that vaccinating young girls against HPV, a sexually transmitted illness, might lead to more unsafe sexual activity in these girls. New evidence, however, suggests that's not the case — and the vaccine could prevent serious health problems.
When Taking Rx Safely Means Taking Birth Control Seriously
For people with severe acne, prescription medication can work when cleansers and ointments fail. Some of those medications, however, can lead to problems if the patient becomes pregnant.
Experts Recommended Against Testosterone Therapy for Healthy Women
When a woman hits menopause, her hormone levels may change substantially. In some cases, menopausal women may need hormone therapy. Today, the Endocrine Society issued its clinical guidelines for androgen therapy in women.
Tefina Increased Number of Orgasms for Women
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a “use-as-required” testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).